Skip to content

Checked

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT04855656 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 1
Interventional
Planned enrollment
464
Participants, all sites
U.S. sites
17
In 13 states

Study details

Conditions
Advanced Solid Tumor
Sponsor
Debiopharm International SA (Industry)
Ages
12 years and older
Sex
All
Healthy volunteers
Not accepted
Start
04/30/2021
Primary completion (expected)
December 2027
Last updated by sponsor
09/22/2026

Full eligibility rules, contacts and site names: NCT04855656 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Los Angeles, San Francisco
  • Connecticut: New Haven
  • Florida: Jacksonville
  • Massachusetts: Boston
  • Michigan: Grand Rapids
  • Minnesota: Rochester
  • Missouri: St Louis
  • New York: New York (2), New Hyde Park
  • Pennsylvania: Philadelphia
  • Rhode Island: Providence (2)
  • Texas: Houston
  • Utah: Salt Lake City
  • Virginia: Charlottesville

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 09/22/2026